Stenting of long coronary artery lesions: Initial angiographic results and 6-month clinical outcome of the micro stent II-XL

✍ Scribed by Martin J. Schalij; Wasan Udayachalerm; Pranobe Oemrawsingh; J. Wouter Jukema; Johan H.C. Reiber; Albert V.G. Bruschke

• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 180 KB
• Volume: 48
• Category: Article
• ISSN: 1522-1946
• DOI: 10.1002/(sici)1522-726x(199909)48:1<105::aid-ccd22>3.0.co;2-0

✦ Synopsis

To evaluate the results of long Micro Stent II (MS-XL) implantations, 119 MS-XLs were implanted in 102 patients (age, 62.83 years). Nineteen stents (16%) were implanted in saphenous vein grafts; 100 stents (84%) were implanted in native coronary arteries. Twenty-five patients (25%) were treated because of acute myocardial infarction (AMI); 30 patients (29%) because of unstable angina or angina class IV, and 47 patients (46%) because of stable angina. Eighty-six de novo lesions (84%) and 16 restenotic lesions (16%) were treated. Indications for stent implantation include elective, 61 patients (60%); suboptimal balloon angioplasty result, 22 patients (21%); and bailout after balloon angioplasty, 19 patients (19%). Because of residual thrombus after stenting, 27 patients (26%) received abciximab. All patients received ticlopidin for 28 days and acetylsalicylic acid. One hundred and seventeen MS-XLs (98%) were implanted successfully. Additional (shorter) MS-II were implanted in 40 patients (39%). The stented segment length was 45 ؎ 20 mm. The minimum lumen diameter increased from 0.5 ؎ 0.5 mm before to 2.7 ؎ 0.5 mm after stent implantation. The acute gain was 2.2 ؎ 0.4 mm. Early clinical events (F4 weeks) include death, 3 (3%); subacute stent thrombosis, 1 (1%); non-Q-wave infarction, 2 (2%); CABG, 1 (1%); vascular complications, 2 (2%). Late clinical events (F6 months) include acute myocardial infarction, 5 (5%); reintervention, 6 (6%); CABG, 1 (1%). The procedural success rate was 88%, and the event free survival at 6 months was 76%. Stenting of long lesions with the MS-XL was successful and associated with an acceptable complication rate.